BCMA and CD38 Combination Therapy for Relapsed Multiple Myeloma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for refractory or relapsed multiple myeloma are inadequate, leading to reduced progression-free survival with each relapse, and there is a need for new therapeutic approaches to effectively manage this condition.
Innovation Solution
Administering a BCMA inhibitor, such as a bispecific anti-BCMA/anti-CD3 antibody, in combination with a CD38 inhibitor, such as daratumumab or isatuximab, in a specific dosing regimen to treat relapsed or refractory multiple myeloma, potentially including a step-up cycle and administration with premedication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with BCMA inhibitor and CD38 inhibitor is administered, then treatment efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent combines two different therapeutic mechanisms (BCMA inhibition and CD38 inhibition) into a single treatment regimen. The BCMA inhibitor (bispecific antibody) and CD38 inhibitor (monoclonal antibody) are administered together to achieve synergistic anti-myeloma effects, addressing the limitation of single-agent therapy while managing the complexity through established combination protocols
2Ease of operation
If BCMA inhibitor is administered alone, then treatment simplicity is maintained, but treatment efficacy is insufficient for refractory or relapsed multiple myeloma
Solution Approach 1:
The patent transitions from monotherapy to combination therapy by administering both BCMA inhibitor and CD38 inhibitor together. This merging of therapeutic approaches targets multiple pathways in multiple myeloma cells simultaneously, overcoming resistance mechanisms that limit single-agent efficacy while maintaining manageable treatment protocols
Data Source
AI summary
The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that bind to BCMA and CD3) in combination with a CD38 inhibitor (e.g., an anti-CD38 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.